With the introduction of the “metal immunology” concept,[27, 28] researchers have developed various manganese (Mn)‐based nanodrugs designed to activate the STING pathway.[29, 30, 31] However, these Mn‐based nanodrugs still encounter challenges, including acute toxicity, aggregation, and rapid metabolism, all of which limit their effectiveness in modulating tumor immune responses. Here, STING1 is linked to neoplasm.